Status:
COMPLETED
Study to Investigate the Activity of AZD5122 When Given as a Single Dose to Healthy Male Subjects
Lead Sponsor:
AstraZeneca
Conditions:
Healthy
Eligibility:
MALE
18-65 years
Phase:
PHASE1
Brief Summary
The purpose of the study is to determine how quickly AZD5122 is absorbed into and cleared by the body when given to healthy, non smoking males at different dose levels. This is a 2 part study, in Part...
Eligibility Criteria
Inclusion
- Provision of signed and dated, written informed consent.
- Normal physical examination, laboratory values, blood pressure and pulse
- Healthy male caucasian subjects
Exclusion
- Subjects must not have any history of gastrointestinal, hepatic or renal disease, or any other condition known to interfere with how drugs are absorbed, used or eliminated by the body.
- Subjects must not have abnormal blood or urine tests for hsCRP, circulating neutrophils, haematocrit, haemoglobin or renal function
- Subjects must not have crystals or more than a trace of blood in their urine
Key Trial Info
Start Date :
September 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2009
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00984477
Start Date
September 1 2009
End Date
November 1 2009
Last Update
December 4 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Nottinghamshire, United Kingdom